Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 53,245	$ 40,056	$ 140,121	$ 96,453
Research and development related success payments and contingent consideration	16,753	4,489	67,778	57,309
General and administrative	13,433	7,099	37,731	19,063
Total operating expenses	83,431	51,644	245,630	172,825
Loss from operations	(83,431)	(51,644)	(245,630)	(172,825)
Interest income, net	158	148	409	622
Other income, net	10	44	24	68
Net loss	$ (83,263)	$ (51,452)	$ (245,197)	$ (172,135)
Net loss per common share - basic and diluted	$ (0.46)	$ (3.76)	$ (1.53)	$ (14.05)
Weighted-average number of common shares - basic and diluted	181,827	13,680	160,515	12,249